ServicenavigationHauptnavigationTrailKarteikarten


Research unit
COST
Project number
C00.0096
Project title
Metal Ion Complexes of Nucleic Acid Constituents with Potentials in Antiviral and Anticancer Therapy (MICAAT)

Texts for this project

 GermanFrenchItalianEnglish
Key words
-
-
-
Anzeigen
Research programs
-
-
-
Anzeigen
Short description
-
-
-
Anzeigen
Partners and International Organizations
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
References in databases
-
-
-
Anzeigen

Inserted texts


CategoryText
Key words
(English)
Adenine Deprotonation; Antivirals; Chelate Formation ;Cisplatin; Intrinsic Basicities; Metal Ion Complexes; Nucleobase Acidifications; Nucleotide Analogues; Stability Constants; Transplatin
Research programs
(English)
COST-Action D20 - Metal Compounds in the Treatment of Cancer and Viral Diseases
Short description
(English)
See abstract
Partners and International Organizations
(English)
AT, BE, BG, CZ, DK, FI, FR, DE, EL, HU, IE, IL, IT, NL, NO, PL, RO, SI, ES, SE, CH, TR, UK
Abstract
(English)
During the time of this report (01.02.2005-23.02.2006) several significant results were obtained; the most pertinent ones follow: (i) Metal ion-binding studies of the dianion of 9-[2-(phosphonoethoxy)ethyl]adenine (PEEA2-) and comparison with previous results for the antivirally active nucleotide analogue 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA2-) reveals that 6-membered chelates involving the ether oxygen in the 'aliphatic' chain are considerably less stable than the corresponding 5-membered ones [Inorg. Chem. 44 (2005) 5104-5117]. Because it has been concluded that the metal ion-ether interaction is crucial for the formation of the reactive intermediate needed in the transfer of a nucleotidyl residue in the polymerase reaction [Chem. Soc. Rev. 34 (2005) 875-900], the mentioned observation offers an explanation why PMEA is a nucleotide analogue with excellent antiviral properties whereas its close relative PEEA is not. PMEA itself is now used in the form of its bis(pivaloyloxymethyl)ester as a drug in hepatitis B therapy. (ii) In nucleic acids metal ion-carbonyl oxygen interactions are expected to occur if support by a primary binding site is provided. This has now been proven to be the case in a study of (N3)-deprotonated uridine, thymidine, and related pyrimidine nucleosides [Proc. Nat. Acad. Sci. USA 102 (2005) 7459-7464]. Similar interactions are expected for the guanine residue, the acid-base properties of which were studied in the dinucleotide d(pGpG) [Org. Biomol. Chem. 4 (2006)]; the corresponding studies with metal ions are in progress. (iii) The coordination chemistry of the anticancer compound Cisplatin, i.e. of cis-(NH3)2PtCl2 or better of its reactive intermediate cis-(NH3)2Pt2+, has been extensively investigated. Much less is known about the inactive analogue Transplatin. We have now studied the complex trans,trans,trans-(NH3)2Pt(N7-µ-9-MeA-N1)2[(NH3)2Pt(9-EtG-N7)]6+2 , where 9-MeA = 9-methyladenine and 9-EtG = 9-ethylguanine, which contains a nucleobase quartett, and discovered to our surprise that one of the adenine (C6)NH2 groups is deprotonated with pKa = 7.1, i.e. in the physiological pH range [to be published]. The biological consequences of this low pKa value are not yet known, but it is certain that this low pKa is due to an intensive H bonding network in the mentioned complex.
References in databases
(English)
Swiss Database: COST-DB of the State Secretariat for Education and Research Hallwylstrasse 4 CH-3003 Berne, Switzerland Tel. +41 31 322 74 82 Swiss Project-Number: C00.0096